Max Marchione is leveraging a $43 million Series A round and a $432 million valuation, alongside an alignment with David Beckham’s supplement company, to scale preventative longevity.
When Max Marchione was a Commerce/Law undergraduate student at the University of Sydney, he weighed up the pros and cons of making a life-and-career-changing decision.
On one side of the scales was what he calls his ‘contrarian mindset, obsession with productivity, and self-driven hunger for learning’ that was pulling him to drop out of uni and understand the world through his own experiences.
On the other side of the ledger, Marchione says, was graduating with a law degree that “teaches you to think, looks good on the résumé, and shows you are smart.”
Avoiding the opportunity cost of spending the next two years in law school won out, and Marchione embarked on self-guided deep dives into crypto, medtech, AI, longevity and venture capital.
Four years later, Marchione is living in San Francisco, has raised more than AUD$65 million for his longevity startup, and is negotiating with David Beckham’s IM8 over a supplement partnership.
At the heart of the new life Marchione built – alongside co-founders Jacob Peter and Kevin Unkrich – is $432 million Superpower, described as a health ‘super app.’ What sets it apart from other players in the health ecosystem is supermaxxing this generation’s access to data.
“We’ve built a super-app offering annual lab testing that analyses over 100 biomarkers across 17 categories of health – 10x more comprehensive than a traditional physical,” Superpower says.
All of that data shifts the focus from reactive healthcare to proactive, enabling subscribers to understand what’s going on internally before it shows up externally.
The value of the David Beckham-backed supplement partnership lies in the ability to create a bio-feedback loop between measurement (Supenormal) and solutions (IM8.)
“That feedback loop has never existed in consumer health until now. IM8 gives our members a supplement protocol we can stand behind with full confidence – clinical-grade formulations built for the same standard of evidence our platform is built on,” says Marchione.
Danny Yeung, the CEO of IM8 parent company Prenetics, says his customers can now access Superpower’s services at a reduced rate.
“With Superpower, an IM8 customer can now test 100+ biomarkers, take our products for 90 days, retest, and see measurable results,” says Danny Yeung, the CEO of IM8.
Costs, tests, and acquisitions
Superpower’s ‘baseline test’ costs USD$199 a year, and includes 100+ biomarkers, according to the company. Add-on diagnostics can be added to detect heavy metals ($129), environmental toxins ($299), gut microbiome ($239).
The $849 Grail Galleri blood screening test was added as an optional panel in March, which can detect a signal associated with more than 50 types of cancer.
The Grail news comes on the back of two acquisitions the company made in 2025 – Feminade, focused on women’s hormone and reproductive health, and at-home diagnostics provider Base. Post-acquisition, Superpower can now offer specific female fertility panels, alongside optional (and additional cost) cardiovascular, autoimmunity and coeliac diagnostics.
The extent of Superpower’s testing is the subject of a California lawsuit by US competitor Function Health, which claims that the company is incorrectly marketing the extent of its biomarker tests.
Marchione denies those allegations and remains focused on scaling the company, noting it has grown revenue by 10x over the last six months.
“We’ve built one of the best teams on the planet to do this: 15 former founders, 3 ex-YC founders, Thiel fellow and many others,” Marchione wrote in a LinkedIn post recently. “This is what the future of health looks like: data in, protocol out, results measured.”
Want to see more Forbes articles on your feed? Tap here to make Forbes Australia a preferred source on Google.
Look back on the week that was with hand-picked articles from Australia and around the world. Sign up to the Forbes Australia newsletter here or become a member here.
